Advertisement
Perspective

The Role of Medical Structural Genomics in Discovering New Drugs for Infectious Diseases

  • Wesley C. Van Voorhis,

    Affiliation: Department of Medicine, University of Washington, Seattle, Washington, United States of America

    X
  • Wim G. J. Hol,

    Affiliation: Department of Biochemistry, University of Washington, Seattle, Washington, United States of America

    X
  • Peter J. Myler mail,

    peter.myler@sbri.org (PJM); Lstewart@decode.com (LJS)

    Affiliations: Seattle Biomedical Research Institute, Seattle, Washington, United States of America, Department of Global Health, University of Washington, Seattle, Washington, United States of America, Department of Medical Education and Biomedical Informatics, University of Washington, Seattle, Washington, United States of America

    X
  • Lance J. Stewart mail

    peter.myler@sbri.org (PJM); Lstewart@decode.com (LJS)

    Affiliation: deCODE biostructures, Bainbridge Island, Washington, United States of America

    X
  • Published: October 26, 2009
  • DOI: 10.1371/journal.pcbi.1000530
  • Featured in PLOS Collections

About the Authors

Wesley C. Van Voorhis
Department of Medicine, University of Washington, Seattle, Washington, United States of America
Wim G. J. Hol
Department of Biochemistry, University of Washington, Seattle, Washington, United States of America
Peter J. Myler
Seattle Biomedical Research Institute, Seattle, Washington, United States of America
Peter J. Myler
Department of Global Health, University of Washington, Seattle, Washington, United States of America
Peter J. Myler
Department of Medical Education and Biomedical Informatics, University of Washington, Seattle, Washington, United States of America
Lance J. Stewart
deCODE biostructures, Bainbridge Island, Washington, United States of America

Corresponding Authors

Competing Interests

Co-author Lance Stewart is an employee of deCODE biostructures, which developed the Fragments-of-Life library presented in Figure 1 and discussed in sections titled ‘Fragment-based drug discovery’ and ‘Targeting oligomeric enzymes’. Fragments-of-Life TM is a technology trademarked by deCODE biostructures and chemistry (http://www.decodechembio.com/Capabilities/StructuralBiology/FragmentsofLife.aspx).